2. Academic Validation
  3. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion

A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion

  • Bioorg Med Chem Lett. 2022 Apr 1;61:128614. doi: 10.1016/j.bmcl.2022.128614.
Matthew J Rybin 1,  Mayra Juliana Laverde-Paz 2,  Robert K Suter 3,  Maurizio Affer 4,  Nagi G Ayad 5,  Yangbo Feng 6,  Zane Zeier 7
Affiliations

Affiliations

  • 1 Department of Psychiatry and Behavioral Sciences, Sylvester Comprehensive Cancer Center, and Center for Therapeutic Innovation, University of Miami, Miami, FL 33136, USA. Electronic address: mxr2011@miami.edu.
  • 2 Department of Psychiatry and Behavioral Sciences, Sylvester Comprehensive Cancer Center, and Center for Therapeutic Innovation, University of Miami, Miami, FL 33136, USA. Electronic address: mjl262@med.miami.edu.
  • 3 Department of Neurological Surgery, Miami Project to Cure Paralysis, and Center for Therapeutic Innovation, University of Miami, Miami, FL 33136, USA; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA. Electronic address: rks77@miami.edu.
  • 4 Department of Neurological Surgery, Miami Project to Cure Paralysis, and Center for Therapeutic Innovation, University of Miami, Miami, FL 33136, USA. Electronic address: mxa2131@med.miami.edu.
  • 5 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA. Electronic address: na853@georgetown.edu.
  • 6 Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, and Center for Therapeutic Innovation, University of Miami, Miami, FL 33136, USA. Electronic address: yxf423@med.miami.edu.
  • 7 Department of Psychiatry and Behavioral Sciences, Sylvester Comprehensive Cancer Center, and Center for Therapeutic Innovation, University of Miami, Miami, FL 33136, USA. Electronic address: zzeier@med.miami.edu.
PMID: 35151865 DOI: 10.1016/j.bmcl.2022.128614
Abstract

High rates of recurrence and treatment resistance in the most common malignant adult brain Cancer, glioblastoma (GBM), suggest that monotherapies are not sufficiently effective. Combination therapies are increasingly pursued, but the possibility of adverse drug-drug interactions may preclude clinical implementation. Developing single molecules with multiple targets is a feasible alternative strategy to identify effective and tolerable pharmacotherapies for GBM. Here, we report the development of a novel, first-in-class, dual aurora and lim kinase inhibitor termed F114. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Due to the importance of these cellular functions, inhibitors of aurora kinases and lim kinases are being pursued separately as anti-cancer therapies. Using in vitro and ex vivo models of GBM, we found that F114 inhibits GBM proliferation and invasion. These results establish F114 as a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future drug development efforts for GBM, and potentially Other cancers.

Keywords

Aurora kinase A (AURKA); Aurora kinase B (AURKB); Aurora kinase C (AURKC); Aurora kinases (AURKs); Fluorescence activated cell sorting (FACS); Glioblastoma (GBM); Induced pluripotent stem cell (iPSC); Lim kinase 1 (LIMK1); Lim kinase 2 (LIMK2); Lim kinases (LIMKs); Temozolomide (TMZ).

Figures
Products